---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 18, 2013

THERMOGENESIS CORP.

(Exact name of registrant as specified in its charter)

 

2711 Citrus Road

(Address and telephone number of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

x	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

    

Item 8.01

Other Events

Attached hereto as Exhibit 99.1 and incorporated by reference herein is a PowerPoint presentation of ThermoGenesis Corp. in connection with the Agreement and Plan of Merger and Reorganization, dated July 15, 2013, among the Company, TotipotentRx Corporation and others.  ThermoGenesis is re-filing the PowerPoint presentation to supplement presentation notes from its prior presentation.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

99.1

Corporate Presentation: The Merger of ThermoGenesis Corp. and TotipotentRx July 2013

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

3

---